Announcements Trials
Browse Landscape

Phase

Phase 3 8Phase 2 6Phase NA 1Phase 4 1Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Completed 6

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 6

Sponsor

Cancer Type

Classical hematology 2Tumor-Agnostic 1Other 1

Conditions

Neoplasms 6Pain 3Burns 2Breakthrough Pain 2Anemia, Sickle Cell 2Agnosia 2Pain, Postoperative 1Pain, Intractable 1Lung Neoplasms 1Intrathecal Dexmedetomidine 1Dyspnea, Paroxysmal 1Colonic Neoplasms 1Cancer Pain 1Breast Neoplasms 1Bone Metastases 1

Interventions

Gemcitabine 53Bevacizumab 52Cyclophosphamide 49Docetaxel 42Carboplatin 40pembrolizumab 37Paclitaxel 36Fluorouracil 36Cisplatin 35Radiotherapy 31Oxaliplatin 31Capecitabine 29Irinotecan 28Dexamethasone 27Leucovorin 25Cetuximab 25Nivolumab 24Doxorubicin 22Drug Therapy 21Erlotinib Hydrochloride 20Pemetrexed 19durvalumab 18trametinib 17fludarabine 16atezolizumab 16Trastuzumab 16Sunitinib 16Rituximab 16Prednisone 16Sorafenib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms × Fentanyl × Clear all
NCT04635852 2020-11-19

EFFENDYS

University of Cologne

Phase 2 Completed
10 enrolled
Other

Dyspnea, Paroxysmal, Neoplasms

NCT01516684 2019-09-06

Local Anesthetic Cream in Younger Patients Undergoing Lumbar Punctures

Wake Forest University Health Sciences

Phase 2 Completed
33 enrolled 6 charts
Tumor-Agnostic

Neoplasms

NCT00236041 2014-05-09

Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Completed
38 enrolled
Classical hematology

Agnosia, Anemia, Sickle Cell, Burns, Neoplasms, Breakthrough Pain

NCT00236093 2014-05-09

Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Completed
Classical hematology

Anemia, Sickle Cell, Burns, Neoplasms, Pain

NCT00355628 2012-08-31

Clinical Study of KW-2246 in Patients With Cancer Pain

Kyowa Kirin Co., Ltd.

Phase 2 Completed
40 enrolled

Neoplasms, Pain

NCT00345735 2012-05-07

Intranasal Fentanyl for the Treatment of Breakthrough Pain in Cancer Patients (FT-017-IM)

Nycomed

Phase 2 Completed
150 enrolled

Neoplasms, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡